A b s t r a c t
Chondromyxoid fibroma was first described by Jaffe and Lichtenstein 1 in 1948 and is defined as a "benign tumor characterized by lobulated areas of spindle-shaped or stellate cells with abundant myxoid or chondroid intercellular material, separated by zones of more cellular tissue rich in spindleshaped or rounded cells with a varying number of multinucleated giant cells of different sizes" (World Health Organization definition). It represents fewer than 1% of all bone tumors and can occur in all age groups (3-70 years), although it mostly affects patients in the second and third decades of life. 2 Typical chondromyxoid fibroma is characterized histologically by extensive myxomatous areas surrounded in a lobular pattern by a more cellular rim. In addition, areas of putative chondroid and, less often, fibrous differentiation can be found. 2, 3 So far, despite many case reports and some larger clinicopathologic studies, [2] [3] [4] no analyses of the biochemical composition of the tumor matrix and only a few studies of the cell differentiation pattern in these neoplasms have been performed. Thus, there is considerable confusion about the basic biology of chondromyxoid fibromas. Whereas Jaffe and Lichtenstein 1 suggested it to be a fibroma with focal chondroid metaplasia, others estimated chondromyxoid fibroma as intermediate in terms of chondroid differentiation in between chondroblastoma and enchondroma. 3, 5 To study cell and tissue differentiation in mesenchymal neoplasms is particularly difficult as mere morphologic evaluation is insufficient for the identification of various mesenchymal tissue types. Recently, Aigner et al 6 were able to show that "pink-chondroid" areas in chondroblastomas do not imply real chondroid matrix formation.
In this article, we present the first analysis of matrix biochemistry and gene expression pattern in chondromyxoid fibroma. We analyzed the expression analysis of matrix components, which are highly characteristic for different differentiation phenotypes of mesenchymal cells (for review see van der Rest and Garrone 7 ). Fibroblastic cells express collagen types I, III, and VI, whereas differentiated chondrocytes typically express collagen type II and aggrecan proteoglycan. Thus, expression analysis of matrix components, particularly of collagens, can serve as marker systems for cell differentiation patterns in mesenchymal neoplasms. 8, 9 
Materials and Methods

Tissue Preparation and Histologic Evaluation
Specimens from cases of chondromyxoid fibromas from the Mayo Bone Tumor Registry, Rochester, MN, and the Department of Pathology, University of Erlangen-Nürnberg, Erlangen, Germany, were used for the study (6 women; 9 men; age range, 18-75 years). 2 The material was fixed routinely with 10% formalin, decalcified if necessary, and completely embedded in paraffin. After histologic evaluation of all samples, 2 one block showing the most relevant histology was selected and processed further for the study.
Histochemical Methods
Histochemical techniques were used to estimate the total content of cartilage typical glycosaminoglycans and collagens on a semiquantitative basis.
Glycosaminoglycans
The cartilage-typical glycosaminoglycans were visualized by toluidine blue staining (10 minutes, 0.3% toluidine blue [Merck, Darmstadt, Germany]; pH 3.65, room temperature). 10 
Collagens
The presence of collagens in the extracellular tumor matrix was demonstrated by Masson-Goldner stain.
Immunohistochemical Analysis
Deparaffinized sections were pretreated enzymatically ❚Table 1❚, incubated with primary antibodies (Table 1) overnight at 4°C, and visualized using a streptavidin-biotincomplex technique (Super Sensitive Immunodetection System for mouse and rabbit primary antibodies, BioGenex, Mainz, Germany) with alkaline phosphatase as the detection enzyme and 3-hydroxy-2-naphtylacid 2,4-dimethylanilide as the substrate. Nuclei were counterstained with hematoxylin.
As the negative control for immunohistochemical stains, the primary antibody was replaced by nonimmune serum (BioGenex, San Ramon, CA) or tris(hydroxymethyl)-aminomethane-buffered saline (pH 7.2).
Probe Selection and Generation-In Situ Hybridization
Suitable fragments of human collagen chains alpha 1 (I) and alpha 1 (II) and aggrecan core protein messenger RNA (mRNA) were selected and transcribed in vitro to generate digoxigenin-labeled antisense and sense riboprobes as described previously. 11, 12 In situ hybridization was performed as described elsewhere. 12 To control for probe specificity, all probes were tested on fetal growth plate specimens in parallel experiments. 11 A probe for 18S ribosomal RNA was used as a positive control.
Detection of Ki-67 Proliferation-Associated Antigen
Paraffin sections were dewaxed, rehydrated, and processed by microwave heating in citrate buffer (pH 6.0) as described by Cattoretti et al 13 with the Mib-1 antibody (Table  1) . Immunohistochemical analysis was performed as described earlier.
Results
The major results for the different tumor areas are summarized in ❚Table 2❚. 
Histologic Features-Cell and Tissue Morphologic Features
All chondromyxoid fibroma specimens analyzed exhibited the characteristic histomorphologic features of chondromyxoid fibroma previously described. 2, 14 The basic cells were stellate or spindle shaped. Neoplastic cells were arranged in lobules in a myxoid background ❚Image 1A❚. A hypocellular center was surrounded by a more cellular periphery. Focally, chondroid areas were observed with rounded cells lying in cell lacunae in 5 of 15 cases ❚Image 2A❚. In some cases giant cells were found, mainly in the peripheral areas.
Cytoprotein Analysis
Whereas the neoplastic cells throughout chondromyxoid fibromas were positive for vimentin, in only 4 of 15 cases were a limited number of cells in the chondroid areas positive for S-100 protein ❚Image 2J❚. None of the cells in the cellular, myxoid, and chondromyxoid areas, which represented the large majority of all tumor cells, were positive ❚Image 1G❚. Eleven cases were completely negative for S-100 protein in the sections analyzed.
Collagen Distribution
Histochemical staining demonstrated a very low overall collagen content in the lobular myxoid tumor areas ❚Image 1E❚, whereas moderate amounts were detectable in the cellular rims of the tumor lobules. A high collagen content was observed in the chondroid tumor areas ❚Image 2G❚. Immunoanalysis of collagen types showed type II collagen mostly present in chondroid tumor portions ❚Image 2F❚. Type II collagen was focally found also in spindle cell areas, indicating a transitional chondromyxoid phenotype of the neoplastic cells in these areas. However, the vast majority of myxoid tumor areas were consistently negative for type II collagen ❚Image 1F❚.
Collagen types I, III, and VI were observed throughout the neoplasms without any specific staining pattern, except that in chondroid tumor areas, type VI collagen was concentrated in the immediate pericellular matrix ❚Image 2I❚.
Collagen Gene Expression Analysis
In situ hybridization analysis on the mRNA level confirmed the protein expression pattern found by immunohistochemical analysis. Type II collagen mRNA expression was restricted to the tumor areas that had shown positive immunohistochemical staining for type II collagen ❚Image 2H❚ and was not observed in the myxoid and cellular tumor portions. In contrast, positive labeling could be seen for type I collagen mRNA expression in these areas ❚Image 1D❚.
Aggrecan Proteoglycan Distribution and Expression
Histochemically, glycosaminoglycans were present at moderate levels throughout the tumor ❚Image 1B❚ and ❚Image 2B❚, but never at the high concentrations seen in hyaline cartilage, chondromas, and well-differentiated chondrosarcomas. 8, 15 In situ hybridization ❚Image 1C❚ and ❚Image 2E❚ and immunolocalization ❚Image 2C❚ and ❚Image 2D❚ allowed us to identify the expression and deposition of aggrecan proteoglycan in the neoplastic cells throughout the neoplasms.
Cell Proliferation
The analysis of the cell proliferation pattern in chondromyxoid fibromas showed a rather high proliferation rate in the cellular, matrix-poor tumor areas rimming the tumor lobules (up to 15%; average, 8%). Low proliferative activity (average 1.5%) was detected in the myxoid tumor areas, and hardly any was detected in the chondroid, matrix-rich tumor portions (only exceptional cells; average, <0.5%). Thus, overall proliferative activity was clearly positively correlated with cellularity and negatively with matrix abundance.
Discussion
The central biochemical feature of chondromyxoid fibroma is the lack of a high collagen concentration in the myxoid tumor areas, which allows extensive hydration of the charged proteoglycan molecules, as demonstrated histochemically. 16 These proteoglycans were at least in part identified as aggrecan, the large aggregating proteoglycan of cartilage. 17 Thus, the histomorphologic variability between different tumor areas depends on the different matrix components and their ratio; that is, a high amount of collagen restricts water binding of proteoglycan and results in a compact matrix formation. Inversely, low collagen content leads to full hydration and to the characteristic myxoid appearance of the extracellular tumor matrix. The focal expression of collagen type II in chondroid areas of chondromyxoid fibroma confirms, on the mRNA and protein levels, findings of previous morphologic studies claiming the presence of cartilaginous matrix and differentiated chondrocytes in chondromyxoid fibroma 5, [18] [19] [20] and rejects others, 21, 22 which doubted the presence of real cartilage formation in chondromyxoid fibroma. The positivity of neoplastic cells for S-100 protein in the chondroid areas provides further support for the chondrocytic differentiation of these cells. 19, 22, 23 However, S-100 protein is not a reliable marker for chondrocytic differentiation, even in mesenchymal neoplasms, as shown for chondroblastomas. 6 ❚Image 1❚ Histologic, histochemical, immunohistochemical, and in situ hybridization analysis of cellular (peripheral) and myxoid tumor areas of chondromyxoid fibromas. Conventional H&E staining (A). Demonstration of the presence of proteoglycans (B) and the absence of significant amounts of collagens (E) (B, toluidine blue; E, Masson Goldner). In situ hybridization analysis showed the messenger RNA expression of aggrecan proteoglycan (C) and type I collagen (D) in the cellular and myxoid tumor areas. Immunostaining for neither type II collagen (F) nor S-100 protein (G) was positive in myxoid tumor areas. In G, note positive nonneoplastic nerve cells in the surrounding tissue and the absence of staining within the tumor cells (A-G, original magnification ×50). Also, the relative scarcity of positive cells with significant numbers of specimens being completely negative 24 largely excludes S-100 protein as a useful positive diagnostic marker for chondromyxoid fibroma, as suggested previously. 22, 23 Our immunohistochemical results are in line with previous ultrastructural data, which revealed not only typical type I through III collagen fibrils but also fine filaments throughout the extracellular tumor matrix. 5, 25, 26 These fine filaments represent at least in part type VI collagen, which also explains the presence of the highly characteristic banded type VI collagen suprastructure, observed by Tornberg and colleagues 27 and Bruns. 28 We also could identify proteoglycan-like granules 18, 22, 25 as aggrecan.
Many of the studied chondromyxoid fibromas showed a rather high proliferation index, which was not evident from conventional histologic evaluation, which showed no or almost no mitotic activity. 2, [29] [30] [31] The proliferating cell fraction was far higher than the proliferation indices of enchondromas or low-grade chondrosarcomas. 32, 33 This would explain the rather high recurrence rate of this lesion compared with other benign lesions of the skeleton. 3, 34 Notably, the proliferation index correlated negatively with matrix abundance and differentiation of the cells. This fits the concept that accumulation of extracellular matrix requires time and chondrocytic differentiation implies reduction of proliferative activity.
The histogenetic origin and classification of chondromyxoid fibroma remains unclear. Jaffe and Lichtenstein 1 suggested it was a fibroma associated with chondroid metaplasia. Schajowitz 16 6 Our data provide additional biologic markers, which might help in the differential diagnosis of chondrogenic bone tumors. Thus, the distinction of chondromyxoid fibroma and chondroblastoma is to some extent controversial and mainly based on their different localizations in bone. Epidemiologic similarities, as well as partly overlapping histologic, 2, 31, 35 histochemical, 4 and ultrastructural 5 features, suggested a close relationship between both entities. In fact, both are mesenchymal neoplasms of unclear origin and both show expression of aggrecan proteoglycan, for example. 6 However, as chondroblastomas do not show chondrocytic differentiation, 6 the presence of neoplastic cartilage formation clearly argues for chondromyxoid fibroma in unclear cases.
Overall, we were able to prove the chondrogenic potential of chondromyxoid fibroma and to demonstrate a so far unique biochemical composition and gene expression pattern, not found in other mesenchymal neoplasms studied previously, including chondroblastoma, osteochondroma, enchondroma, and chondrosarcoma. This justifies chondromyxoid fibroma as a specific tumor entity. Matrix composition analysis is able to explain much of the histomorphology of these neoplasms, but is additionally able to give insights into their basic cell biology, which is one determinant of their clinical behavior. More knowledge of tumor biology will allow more accurate classification, understanding, and treatment of these neoplasms in the future.
